Pelthos Therapeutics Inc.: director Ezra M. Friedberg sold 558 shares

What happened Ezra M. Friedberg, a director, sold 558 shares in an open-market or private sale (code S) at $20.72 per share on Oct 02, 2026, for $11,560. The filing notes the transaction was made under a Rule 10b5-1 plan and was to satisfy estimated tax obligations related to the vesting of restricted stock units.

Key details

• Transaction date and price: Oct 02, 2026 — 558 shares sold at $20.72 per share, total proceeds $11,560.
• Transaction type: Open-market or private sale (code S).
• Shares owned after the transaction: not provided in the supplied filing.
• Footnotes: F1 — sale pursuant to a Rule 10b5-1 plan adopted Dec 16, 2025 to satisfy estimated tax obligations in connection with RSU vesting; F2 — Mr. Friedberg is manager of Balmoral Financial Group LLC and Key Recovery Group LLC and may be deemed to beneficially own shares held by those entities but disclaims such ownership except to the extent of his pecuniary interest.
• Filing timeliness: the filing does not indicate a late filing.

Why it may matter The filing shows the sale was executed under a pre-established Rule 10b5-1 plan and was linked to tax obligations from RSU vesting, and it discloses potential deemed beneficial ownership through entities Mr. Friedberg manages (which he disclaims except for pecuniary interest). This filing does not show why the insider traded or why the company acted.